• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Lianbio

Headquarters: Shanghai, China
Year Founded: 2020
Status: Public
Industry Sector: HealthTechnology
CEO: Adam Leo Stone
Number Of Employees: N/A
Enterprise Value: $-80,628,932
PE Ratio: 0.06
Exchange/Ticker 1: Pink:LIANY
Exchange/Ticker 2: N/A
Latest Market Cap: $21,720,300

BioCentury | Feb 25, 2025
Deals

Counteroffer from Tang-backed Concentra could scuttle Acelyrin-Alumis: Deals Report

Plus Radiance gets ROR1 ADC from Cspc, Astrazeneca buys Fibrogen’s China subsidiary and more
BioCentury | Feb 17, 2024
Finance

Public equity report: Five follow-ons total $875M+, PIPEs keep flowing

Plus: LianBio begins winding down, promises dividend; BioXcel pulls offering
BioCentury | Dec 21, 2023
Management Tracks

Larson leaving LianBio as CFO

Plus: Claypoole becomes CEO of Bioventus, and updates from Boston Pharma, Atlas, Quest, Scribe, 858 and more
BioCentury | Dec 20, 2023
Management Tracks

Abernethy leaving Verily for non-profit

Plus: CEO Wang leaving LianBio and more from Bicara and Hervolution, ImPact
BioCentury | Oct 31, 2023
Deals

Oct. 31 Quick Takes: Lilly buying Beam’s opt-in rights for Verve base editing programs

Plus: GSK buys Janssen’s rights to Arrowhead HBV product and more from  Galapagos, Sarepta, Amgen, LianBio and X4
BioCentury | Oct 25, 2023
Deals

Oct. 24 Quick Takes: BMS buying back Asia rights to mavacamten from LianBio 

Plus: Rampart raises $85M series A for DNA-based therapies and updates from Servier, Novartis, Cargo and more
BioCentury | Jul 26, 2023
Finance

July 26 Quick Takes: Versant’s Nexo launches with $60M series A round

Plus: Mirxes raises $50M series D, files for IPO in Hong Kong and updates from Kriya, Kincell, Tarsus, Infinity-MEI
BioCentury | Jun 1, 2023
Data Byte

At least 15 PDUFA dates on FDA’s calendar for June

Expected decisions include BioMarin’s hemophilia A gene therapy, a subQ form of argenx’s of myasthenia gravis drug, and Aldeyra’s retinal cancer candidate
BioCentury | Apr 21, 2023
Management Tracks

Allogene hires former Kite exec Moore

Plus: LianBio promotes Pascal to CCO and updates from Ocuphire and ImmVira
BioCentury | Apr 21, 2023
Regulation

April 21 Quick Takes: LianBio’s mavacamten gets priority review in China

Plus: FDA extends PDUFA for Daiichi’s quizartinib, and updates from AbbVie, Apellis and more
Items per page:
1 - 10 of 50
Help Center
Username
Request a Demo
Request Training
Ask a Question